

Karen Strambler, Office of Policy
Office of the Commissioner, Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
Phone: 301-827-3360
Fax 301-594-6777; e-mail: Karen.Strambler@fda.gov.

Re: Public Hearing, Task Force on Drug Importation, April 14, 2004 (9am to 5pm)
Natcher Auditorium, Building 45, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892

(Docket No. 2004N-0115) Prescription Drug Importation Public Meeting

Presenter Information:

Noel T. (Tom) Curb, R.Ph. (Affiliations: SPC Global Technologies, Ltd. and Expedite-Rx)
Home: 9830 FM 2843, Salado, TX 76571 Office: 2801 W. Avenue T, Temple, TX 76504

Phones - Office: 254-773-3728; Home: 254-947-5531; Cell: 254-718-1378
e-mail - tomcurb@drugbenefit.com
Fax - 254-774-8155

Requested Time Allocation: 30 (Thirty) to 45 (Forty-Five) Minutes

Outline of Discussion:

(Commentary/Projections: Current Situation; Importation Phases/Impact – individual, bulk, discounted pricing; Industry Reaction; Overall Impact – Consumers/Retailers; Experiences – safety, financial; Obligations/Responsibilities of Health Care Entities)

- I. **Safety Issues**
 - A. General (product related; sourcing accountability)
 - B. Specific (FDA's role/ability; U.S. internal distribution system; technology)
- II. **Regulatory/Legislative Issues**
 - A. FDA certification
 - B. Levels of Risk (domestic/foreign)
- III. **Technology (Improved Safety)**
 - A. Anti-Counterfeiting
 - B. Costs
- IV. **Financial Impact**
 - A. Short-Term
 - B. Long-Term
 - C. Other
- V. **R and D**
 - A. Impact on Consumers and Patients
 - B. Investment
- VI. **Liability Issues**
 - A. Bulk Importation
 - B. Individual Importation
 1. Source Accountability
 2. Technology
- VII. **Foreign Health Agencies**
 - A. Reciprocity (Medical; Pharmaceutical)
 - B. Regulatory